@article {Elyazar2020.12.14.20248159, author = {Iqbal RF Elyazar and Henry Surendra and Lenny L Ekawati and Bimandra A. Djaafara and Ahmad Nurhasim and Ahmad Arif and Irma Hidayana and Widyastuti and Dwi Oktavia and Verry Adrian and Ngabila Salama and Imam Hamdi and Adhi Andrianto and Rosa N Lina and Karin D Lestari and Anuraj H Shankar and Raph L Hamers and Guy Thwaites and J. Kevin Baird}, title = {Excess mortality during the first ten months of COVID-19 epidemic at Jakarta, Indonesia}, elocation-id = {2020.12.14.20248159}, year = {2020}, doi = {10.1101/2020.12.14.20248159}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Excess mortality during the COVID-19 epidemic is an important measure of health impacts. We examined mortality records from January 2015 to October 2020 from government sources at Jakarta, Indonesia: 1) burials in public cemeteries; 2) civil death registration; and 3) health authority death registration. During 2015-2019, an average of 26,342 burials occurred each year from January to October. During the same period of 2020, there were 42,460 burials, an excess of 61\%. Burial activities began surging in early January 2020, two months before the first official laboratory confirmation of SARS-CoV-2 infection in Indonesia in March 2020. Analysis of civil death registrations or health authority death registration showed insensitive trends during 2020. Burial records indicated substantially increased mortality associated with the onset of and ongoing COVID-19 epidemic in Jakarta and suggest that SARS-CoV-2 transmission may have been initiated and progressing at least two months prior to official detection.Article summary line Analysis of civil records of burials in Jakarta, Indonesia showed a 61\% increase during 2020 compared to the previous five years, a trend that began two months prior to first official confirmation of SARS-CoV-2 transmission in the city.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Wellcome Trust, UK (106680/Z/14/Z). The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of this paper.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Health Research Ethics Committee of the National Institute of Health Research and Development, Ministry of Health Indonesia (LB.02.02/2/KE.554/2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and analyzed during the current study are available from the corresponding author on reasonable request}, URL = {https://www.medrxiv.org/content/early/2020/12/14/2020.12.14.20248159}, eprint = {https://www.medrxiv.org/content/early/2020/12/14/2020.12.14.20248159.full.pdf}, journal = {medRxiv} }